



Research Article

**METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ROSUVASTATIN CALCIUM AND EZETIMIBE IN PHARMACEUTICAL DOSAGE FORM BY RP-HPLC**

M.M.Eswarudu\*, P.Mounica, D.Venkatesh, B.Nagalakshmi.

Department of pharmaceutical Analysis, Anurag pharmacy college, Ananthagiri(V), Kodad(M), Nalgonda (Dt), Andhra Pradesh, 508206, India.

(Received: 14 Feb, 2012; Accepted: 20 Feb, 2012; Published: 29 Feb, 2012)

\*Corresponding author's email: [eswarmunnangi@gmail.com](mailto:eswarmunnangi@gmail.com)

**ABSTRACT**

A simple, precise and efficient high performance liquid chromatographic method was developed for simultaneous determination of Rosuvastatin calcium and Ezetimibe in tablets. A symmetry C<sub>18</sub> column 75×4.6mm i.d. 3.5μ in isocratic mode with mobile phase containing Acetonitrile: methanol: buffer (0.01M sod.dihydrogen phosphate) (30:20:50 v/v) pH adjusted to 3.0 using ortho phosphoric acid (v/v). The flow rate was 1.0 ml/min and effluent was monitored at 263 nm. The retention time and linearity range for Rosuvastatin calcium and Ezetimibe were (3.88, 8.16 min) and (10-60, 10-60 μg/ml), respectively. The validation of the proposed method was carried out for its specificity, linearity, accuracy, precision, limit of detection and quantification for both Rosuvastatin calcium and Ezetimibe. The developed method can be used for simultaneous determination of Rosuvastatin calcium and Ezetimibe in tablet dosage form.

**KEYWORDS:** Rosuvastatin calcium, Ezetimibe, RP- HPLC, Optimization and Validation.


**INTRODUCTION**

Rosuvastatin, new member of a class of cholesterol lowering drugs commonly referred to as “statins”, was approved for the treatment of dyslipidemia<sup>(1-3)</sup>.


Rosuvastatin (RST) is chemically bis [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S)-3, 5-dihydroxy hept- 6-enoic acid] calcium salt. RST, a

synthetic lipid lowering agent, is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the key rate-limiting enzyme of cholesterol biosynthesis in liver. RST is used to reduce the amounts of LDL cholesterol, total cholesterol, triglycerides and a lipoprotein B in the blood. RST also modestly increases the level of HDL cholesterol in the blood. These actions are important in reducing the risk of atherosclerosis, which in turn can lead to several cardiovascular complications such as heart attack, stroke and peripheral vascular disease. RST peak plasma concentrations were reached by 3–5 hrs following oral administration in humans<sup>4</sup>. Ezetimibe<sup>(5-6)</sup> (3*R*,4*S*)-1-(4-fluorophenyl)-3-[(3*S*)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidine-2-one, is an anti-hyperlipidemic medication, acts by decreasing cholesterol absorption in the intestine. Both drugs are used in combination to treat dyslipidemia, Hyperlipidemia, hypercholesterolemia and to prevent cardiovascular disease including atherosclerosis. Numbers of reported method were already available for the individual determination of both drugs. Rosuvastatin calcium alone has been determined by Spectrophotometric methods<sup>(7-9)</sup> Stability

indicating method<sup>10</sup>, HPTLC<sup>11</sup> and RP-HPLC<sup>(12-14)</sup>. Ezetimibe was also estimated using UV- method<sup>(15-17)</sup>, Derivative Spectroscopy<sup>(18,19)</sup> and LC-MS/MS<sup>20</sup>. To the best of knowledge, only Three HPLC Methods<sup>(21-23)</sup>, has been developed for the simultaneous determination of both the drugs in tablets. The present research work describes the rapid, accurate, sensitive and reproducible RP-HPLC method for simultaneous estimation of Rosuvastatin Calcium and Ezetimibe from the tablet formulation.



**Figure1:** Molecular structure of Rosuvastatin Calcium



**Figure2:** Molecular structure of Ezetimibe

## EXPERIMENTAL WORK

### Instruments, Reagents and Materials.

High performance liquid chromatograph, Water model e2695 pump LC-10AT VP equipped with Rheodyne inject with 20 $\mu$ l fixed loop. Empower software was used. ROS and EZE pure samples were procured as gifts sample from Dr.Reddys labs, Hyderabad. "ROZAVEL- EZ" tablets (Sun Pharmaceuticals Ltd) were procured from local market. Label claim of Rozavel EZ tablet for ROS and EZE were 10 mg and 10 mg respectively. Methanol HPLC grade, Acetonitrile HPLC grade were purchased from E.Merck (Mumbai, India), sodium Dihydrogen Phosphate and o-phosphoric acid were purchased from SD fine chemical Ltd (Ahmadabad, India) and were of analytical grade Water of HPLC grade was used.

### Chromatographic condition of method

The symmetry C18 column was used at ambient temperature. The mobile phase considered Acetonitrile: Methanol: Sodium dihydrogen phosphate buffer (30:20:50 v/v) pH adjusted to 3.0 $\pm$  0.1 with o-phosphoric acid. It was pumped at flow rate of 1ml/min. The mobile phase was passed through nylon 0.45  $\mu$ m membrane filters and degassed before use. The elution was monitored ROS and EZ at 263 nm and the injection volume was 20  $\mu$ l.

### Preparation of standard stock solution

The equivalent of 10 mg each of ROS and EZE were accurately weighed in 100 ml volumetric flasks separately and dissolve in 25 ml of methanol and 25 ml of Acetonitrile. After the immediate dissolution, the volume was made up to the mark with solvent. These standard stock solutions were observed to contain 100  $\mu$ g/ml of ROS and EZE.


### Preparation of sample solution

20 tablets were taken and their average weight was determined, they were crushed to fine powder. Then powder equivalent to 10 mg of ROS and 10 mg EZE was taken in 100 ml volumetric flask and dissolved in 75ml of methanol with vigorous shaking for 5-10 minutes. The supernatant liquid was transferred to 50ml of volumetric flask through a what's man filter paper. The residue was washed twice with solvent and the combined filtrate was made up to 100ml mark. After that 10 ml of the above solution was diluted up to 100 ml with solvent.

### Uv Spectras of Rosuvastatin and Ezetimibe

Absorbance maxima of Rosuvastatin Calcium and Ezetimibe were detected at 244.40 nm ( $\lambda_2$ ) and 234.00 nm ( $\lambda_1$ ), respectively. Both the spectra's were

overlapped at 263 nm. Both the drugs showed linearity with absorbance in the range 10-60 µg/ml, when measured at 234.00 nm and 244.40 nm. Calibration curves were plotted from the absorbance values at these wavelengths.



**Figure-3:** UV Spectra of Rosuvastatin and Ezetimibe

### 3. METHOD VALIDATION

#### a) Linearity

Calibration graphs were constructed by plotting peak area Vs concentration of ROS and EZE and the regression equation were calculated. The calibration graphs were plotted over 6 different concentrations in the range of 10- 60µg/ml for both drugs. Accurately measured mixed standard solution aliquots of ROS and EZE (1, 2, 3,4,5,6 ml) were transferred to series of 10 ml volumetric flasks and diluted to mark with mobile phase. Aliquots (20µl) of each solution were injected under the operating chromatographic condition described above [Number of replicates (n=6)].

#### b) Accuracy

The accuracy of the method was established using recovery technique i.e. external standard addition method. The known amount of standard was added at three different levels to preanalysed sample. Each determination was performed in triplicate. The result of recovery study is presented in (Table2).

#### c) Method precision (repeatability)

The precision of the instrument was checked by repeatedly injecting (n = 6) mixed standard solution of Rosuvastatin and Ezetimibe.

#### d) Limit of detection (LOD) and limit of quantitation (LOQ)

The LOD with signal to noise (S/N) ratio of 3:1 and LOQ with (S/N) ratio of 10:1 were calculated for both drugs using the following equations according to International Conference on Harmonization guidelines<sup>2</sup>.

$$\text{LOD} = 3.3 \times \sigma/S$$

$$\text{LOQ} = 10 \times \sigma/S$$

Where  $\sigma$  = the standard deviation (SD) of the response and

S = the SD of the y-intercept of the regression line.

**e). Analysis of ROS and EZE in tablet dosage form**

The response of sample solutions were measured at 263 nm for quantitation of ROS and EZE by the method described above. The amount of ROS and EZE present in the sample solution were determined by applying values of peak area to regression equation of the calibration graph.

**4. RESULTS AND DISCUSSION**

To optimize the HPLC parameters, several mobile phase compositions were tried. A satisfactory separation of ROS and EZE with good peak symmetry and steady baseline was obtained with mobile phase Acetonitrile: Methanol: SodiumdihydrogenPhosphate buffer (30:20:50 v/v) adjusted to pH 3.0. Quantitation was achieved with UV detection at 263nm based on peak area. Complete resolution of the peaks with clear baseline separation was obtained (Fig.4)




Fig. 4. High performance liquid chromatogram of ROS and EZE with detection at 263 nm.

**VALIDATION OF THE PROPOSED METHOD**


**a). Linearity**

Linear correlation was obtained between peak areas and concentration of ROS and EZE in the range of 10-60µg/ml for both

the drugs, respectively. Data of the regression analysis are summarized in Table 1

**Rosuvastatin calcium: Table.1.1**

S.No	% of Test	Concentration(µg/ml)	Area
1	25	10	480809
2	50	20	951395
3	75	30	1437366
4	100	40	1935934
5	125	50	2432360
6	150	60	2932530




**Fig. 4. Linearity graph of rosuvastatin calcium**

S.NO	% of test	Concentration(µg/ml)	Area

1	25	10	571993
2	50	20	1132355
3	75	30	1712233
4	100	40	2306834
5	125	50	2895886
6	150	60	3487158

**Ezetimibe: Table.1.2**



**Fig. 5. Linearity graph of Ezetimibe**

**b).Accuracy:**

The recovery experiments were performed by standard addition method. The recoveries obtained were 98.81 + 0.19 % and 99.97 + 03% for ROS and EZE respectively. The result of recovery study is presented in (Table2).

**Rosuvastatin calcium: Table. 2.1**

S.No	Spike Level	µg/ml added	µg/ml found	% recovery	mean % recovery
1	50%	20	19.99	99.99	100.00%
2	50%	20	20.00	100.01	
3	50%	20	19.99	99.99	
1	100%	40	39.85	99.64	99.44%
2	100%	40	39.53	98.84	
3	100%	40	39.94	99.86	
1	150%	60	60.00	100.00	99.99%
2	150%	60	59.99	99.99	
3	150%	60	59.99	99.99	

Ezetimibe:

Table 2.2

S.No	Spike Level	µg/ml found	µg/ml found	mean %recovery	mean %recovery
1	50%	20	39.98	99.95%	99.95%
2	50%	20	39.982	99.95%	
3	50%	20	39.98	99.95%	
1	100%	40	19.99	99.99%	100.01%
2	100%	40	20.00	100.00%	
3	100%	40	20.01	100.05%	
1	150%	60	59.98	99.97%	99.96%



2	150%	60	59.98	99.97%	
3	150%	60	59.96	99.97%	

**c). Method precision**

The RSD values for ROS and EZE were found to be 0.31 % and 0.31% respectively (Table3)

**Rosuvastatin calcium: Table. 3.1**

S.No	Retention Time(min)	Area
1	3.875	1959547
2	3.877	1963087
3	3.88	1961306
4	3.874	1957401
5	3.897	1970034
6	3.928	1972717
Average	3.8885	1964015
S.D	0.021116	6064.009
%R.S.D	<b>0.54</b>	<b>0.31</b>

**Ezetimibe: Table.3.2**

S.No	Retention Time(min)	Area
1	8.128	2332336
2	8.131	2334714
3	8.133	2333381
4	8.123	2329574
5	8.189	2343311
6	8.276	2348093
Average	8.1633	2336902
S.D	0.060321	7183.961
%R.S.D	0.74	0.31

**d). LOD and LOQ**

LOD values for ROS and EZE were found to be 0.407 and 0.405µg/ml respectively.

to be 1.27 and 1.26µg/ml respectively. (Table 4).

LOQ values for ROS and EZE were found

**Table. 4**

Parameter	ROS	EZE
LOD	0.4072µg/ml	0.4055µg/ml
LOQ	1.27090 µg/ml	1.265 µg/ml

**e). Assay of the tablet dosage form (ROS 10mg/tablet and EZE 10mg/tablet)**

The proposed validated method was successfully applied to determine ROS and EZE in tablet dosage form. The result

obtained for ROS and EZE were comparable with corresponding labeled amounts (Table 5).

**Table.5**

Drug	%Assay	Amount Present
<b>Rosuvastatin calcium</b>	99.81	9.98mg/tab
<b>Ezetemibe</b>	99.92	9.92mg/tab

**f).System suitability parameters: Table.6**

Parameter	Acceptance criteria	Observed value
<b>1.Theoretical plates</b>	(not less than 3000)	
Rosuvastatin calcium		3808
Ezetimibe		5938
<b>2.Tailing factor</b>	(not more than 2)	
Rosuvastatin calcium		1.2
Ezetimibe		1.1
<b>3.Repeatability</b>	(RSD <1% for N>5)	
Rosuvastatin calcium		1.2
Ezetimibe		1.1

4.Resolution(Rs)	(Rs>2)	12.54
------------------	--------	-------

## CONCLUSION

The proposed method has advantage of simplicity and convenience for the separation and quantitation of ROS and EZE in the combination and can be used for the assay of their dosage form. Also, the low solvent consumption and short analytical run time lead to environmentally friendly chromatographic procedure. The method is accurate, precise, rapid and selective for simultaneous estimation of Rosuvastatin Calcium and Ezetimibe in tablet dosage form. Hence it can be conveniently adopted for routine analysis.

## Acknowledgements

step of my project work.

## References:

1. Indian Pharmacopoeia. Ghaziabad: The Indian Pharmacopoeia Commission; **2007**; 3: 1676-1678.
2. A.G. Olsson, F. McTaggart, A. Raza, Cardiovascular. *Drug Rev.* **2002**; 20: 303–328.
3. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKinney, E. Miller,

We are grateful to Dr.Reddy's Labs for the gifts sample of Pure ROS and EZE. We are very much thankful to Dr. M. chinna eswaraiah, Principal, Anurag Pharmacy College for his guidance, kind help and constant encouragement at every step during the progress of my work without which successful completion of this work would not have been possible. It is my pleasure to express my sincere thanks to Dr.P.RajeshwarReddy, correspondent and secretary, Amartya educational society, for his providing laboratory facilities and chemicals. I am also grateful to my friends for their kind help from time to time at each and every

V.A. Cain, J.W. Blasetto, *Am. J. Cardiol.* **2003**; 92: 152–160.

4. P.D. Martin, P.D. Mitchell, D.W. Schneck, *Br. J.Clin. Pharmacol.***2002** ;54: 472–477.

5. The Merck Index, 13th Edn., Budavari. S., Eds., Merck & co., Inc., Whitehouse Station, NJ, **2001**.

6. [http://:www.Rxlist.com](http://www.Rxlist.com)

7. Dannana GS, Marothu VK. Extractive Spectrophotometric methods for the determination of Rosuvastatin calcium in pure form and in pharmaceutical formulations by using safranin O and

- methylene blue. *E J Chem* **2007**; 4(1):46-49.
8. Gupta A, Mishra P, Shah K. Simple UV Spectrophotometric determination of Rosuvastatin calcium in pure form and in pharmaceutical formulations. *E J Chem* **2009**; 6(1):89-92.
9. Singh RM, Ansari TA, Jamil S, Kumar Y, Mathur SC, Singh GN. Spectrophotometric estimation of Rosuvastatin calcium in tablet formulation. *Indian Drugs* **2005**; 42(4):244-245.
10. Hasumati AR, Rajput SJ, Dave JB, Patel CN. Development and validation of two chromatographic stability-indicating methods for determination of Rosuvastatin in pure form and pharmaceutical preparation. *Int J ChemTech Res* **2009**; 1 (3):677-689.
11. Singh RM, Jami S, Ansari TA, Mathur SC, Nivoria CS, Pandey MK et al. Determination of Rosuvastatin calcium in pharmaceutical dosage form by RP-HPLC method. *Indian Drugs* **2005**; 42(2):98-101.
12. Singh SS, Sharma K, Patel H, Jain M, Shah H, Gupta S et al. Estimation of Rosuvastatin in Human plasma by HPLC Tandem Mass Spectroscopic method and its application to Bioequivalence study. *J Braz Chem Soc* **2005**; 16(5):944-950.
13. Thammera RK, Shitut NR, Pasikanti KK, Menon VCA, Venkata VPK, Mullangi R et al. Determination of Rosuvastatin in rat plasma by HPLC and its application to pharmacokinetic studies. *Biomed Chromatogr* **2006**; 20(9):881-887.
14. Mishra Pradeep, Gupta Alka, Shah Kamal. Spectrophotometric determination of Ezetimibe in pharmaceutical formulations. *J Indian Chem Soc* **2007**; 84(9):945-947.
15. Jain Nilesh, Jain Ruchi, Swami Hemant, Pandey Sharad and Jain DK. Spectrophotometric method for simultaneous estimation of Simvastatin and Ezetimibe in bulk drug and its combined dosage form. *Int J Pha & Phar Sci* **2009**; (1):171-175.
16. Godse VP, Deodhar MN, Bhosle AV, Sonewane RA, Sakpal PS, Borkar DD et al. Simultaneous spectrophotometric estimation of Ezetimibe and Atrovastatin in pharmaceutical dosage form. *J Research Chem* **2009**; 2(1):86- 89.
17. Samir Mohamed El-Mogahazy, Mohamad Abid El-Azem Mohamed, Marwa Fadel Mohamed, Nadia Fayek Yousef. Development and validation of HPLC, TLC and derivative spectrophotometric methods for the

analysis of Ezetimibe in the presence of alkaline induced

degradation products. *J Chinese Chem Soc* **2009**; 56:360-367.

18. Rajput SJ, Raj HA. Simultaneous estimation of Ezetimibe and Losavastatin by derivative

spectroscopy. *PharmTech* **2009**; 1(3):894-899.

19. Mahadik MV, Dhaneshwar SR. Application of a stability indicating HPTLC method for the

quantitative determination of Ezetimibe in pharmaceutical dosage forms. *Asian. J Pharma*

*Sci* **2007**; 2(5):182-190.

20. Akmar SK, Kothapalli L, Thomas A, Jangam S, Deashpande AD. Reverse phase high

performance liquid chromatography method for estimation of Ezetimibe in bulk and

pharmaceutical formulations. *Ind J Pharm Sci* **2007**; 69(5):695-697.

21. Dixit PR, Chandrasekhar R, Nagashekar SM. Stability indicating HPLC method for

Simultaneous determination of Ezetimibe and Simvastatin. *Asian J Pharm Sci* **2007**; 2(5):182- 190.

22. Anuradha.K.Gajjar and vishal D.Shah.Development And Validation Of Stability Indicating Rp-Hplc Method For

Simultaneous Estimation Of Rosuvastatin Calcium And Ezetimibe From Their Combination Dosage Forms. *Eurasian J Anal Chem* **2010**; 5(3):265-283.

23. Smita Sharma, M. C. Sharma, D. V. Kohli, S. C. Chaturvedi, Optoelectronics and advanced materials – *rapid communications*. *February* **2010**; 4(2): 238 – 241.

24. ICH-Q2B Validation of Analytical Procedures: Methodology International Conference on

Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human

Use, Geneva, Switzerland, 1996.

25. ICH guideline Text on Validation of Analytical Procedures, Step-3: Q2A, **1994**.